Respiratory Tract Articles & Analysis

Imspex Diagnostics’ patent portfolio recently grew, with news that the European Patent Office has granted the patent “Method for measuring human exhaled air”. This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory ...

By Imspex Diagnostics Ltd.

Albuquerque. NM, Nob Hill Therapeutics announced today the appointment of Craig Davies-Cutting, PhD, as Vice President of Research and Development. Dr. Davies-Cutting will contribute his extensive respiratory product development and industry expertise to the development and commercialization of Nob Hill Therapeutics’ first-of-its-kind DryNeb dry powder nebulizer inhalation drug delivery ...

By Nob Hill Therapeutics

Lumex Instruments has developed a rapid modern solution to distinguish COVID-19, Influenza A, and B from the same sample.* It is imperative to differentiate and identify the exact causative virus for appropriate therapeutic intervention, especially during the current COVID-19 pandemic. The solution employs a pre-loaded microchip kit with the primers and probes lyophilized in the microchip for ...

By Lumex Instruments

Nob Hill Therapeutics' Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonary Drug Delivery session on Friday, October 29th at 12:00pm ET. PODD is an annual virtual event where members of the pharma, biotech and drug delivery industries gather to share cutting-edge business and ...

By Nob Hill Therapeutics

Following the development of the spread of the Coronavirus COVID-19, we inform our customers that we are operating in compliance with the regulations and dispositions issued by the Italian Government. Our top priority is the safety and protection of people. In order to continue carrying out our work, we have adopted all the safety systems necessary for the protection of our workers and visitors ...

By Hymach s.r.l.

Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. The IPC focuses on early-stage life science companies actively raising capital and ...

By Nob Hill Therapeutics

The study demonstrated the test’s high performance in distinguishing between bacterial and viral infection Incorporated a broad pediatric population presenting with fever without source and respiratory tract infection MeMed’s test outperformed existing biomarkers of infection MeMed, a leader in the emerging field of advanced hostresponse technologies, today announces positive ...

By MeMed

Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, multi-dose exploratory clinical study with an enrolment of ~60 subjects who are close contacts of ...

By Frontier Biotechnologies Inc.

OM Pharma enters into a strategic collaboration agreement granting AstraZeneca the exclusive right to import and distribute the immunological therapy Broncho-Vaxom® for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan). OM Pharma and AstraZeneca celebrated their strategic collaboration agreement today at a partnership signing ...

By OM Pharma Ltd.

In an article published in Nature Communications, entitled "Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR Associated Nucleases to Airway Epithelia” Dr. David Guay, Research Director of Feldan Therapeutics, and collaborator Dr. Paul McCray, from the University of Iowa Carver College of Medicine, demonstrate that Feldan’s engineered amphiphilic peptides (Feldan ...

By Feldan Therapeutics

The Dieter Lütticken Award 2009, a prestigious international annual award dedicated to alternatives in animal testing for veterinary medicines, goes to Dr. A.W. (Dan) Tucker, senior lecturer in veterinary public health at the University of Cambridge (United Kingdom). He will receive the € 20,000 award, which is sponsored by Intervet/Schering-Plough Animal Health, for the development of ...

By CSRwire - Corporate Social Responsibility Newswire

Fighting the epidemic together – Yaguo and the Shanghai Tianyi Group donated 8-million-yuan worth of innovative respiratory equipment to help Hubei’s new coronavirus pneumonia epidemic. On February 18th 2020, Beijing Yaguo Technology Co., Ltd. (“Yaguo”) and the Shanghai Tianyi Industry Holding Group Co., Ltd. (“Tianyi”) jointly donated medical equipment with a ...

By Beijing Yaguo Technology Co., Ltd.

Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses Streptococcus pneumoniae infections and how they may impact human health. Streptococcus pneumoniae, or pneumococcus, is a type of Gram-positive bacteria. It can often be found in ...

By Cochrane & Associates, LLC

208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...

By OpGen, Inc.

Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses exposure risks and occupational asthma due to a family of chemicals known as isocyanates. Isocyanates are powerful irritants to the mucous membranes of the eyes and gastrointestinal and respiratory tracts. Direct skin contact can also cause marked ...

By Cochrane & Associates, LLC

SOUTH SAN FRANCISCO, Calif, January 10, 2020 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) ...

By Meissa Vaccines, Inc.

The AioCare system is used as a home self-monitoring tool in a prospective, observational cohort study of a drug for severe eosinophilic asthma, produced by one of the world’s pharmaceutical concerns. Fifty adult patients diagnosed with severe eosinophilic asthma (defined by blood eosinophilia ≥300 cells / μl and at least three asthma exacerbations in the previous year) will be ...

By AioCare

Recently, the U.S. Centers for Disease Control (CDC) announced that an additional 4.3 million people were diagnosed with asthma between 2001 and 2009. These new figures bring the total number of asthma suffers in the United States to approximately 1 in 12 or 25 million people. "Despite the fact that outdoor air quality has improved, we've reduced two common asthma triggers - secondhand smoke ...

By Cochrane & Associates, LLC

Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDxTM Sepsis test in patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments is cost-effective versus standard-of-care. The study was published today in The Journal ...

By Inflammatix, Inc.

Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source. This treatments aims to be ...

By Immune Biosolutions Inc.